A study identifies a new cause of blood clots in Corona...

Blood clots continue to wreak havoc in patients who have an infection COVID-19 Severe, and a new study explains what may cause it to occur in up to half of patients.

Corona virus, is an autoimmune antibody that spreads in the blood and attacks cells and leads to clots in arteries, veins and microscopic vessels, and blood clots can cause life-threatening events such as strokes. And in the case COVID-19 , Microscopic clots may restrict blood flow to the lungs, impairing oxygen exchange.

According to researchers at the Michigan Medicine Frankel Center for American Cardiovascular Disease, the relationship between autoantibodies and COVID-19 Unexpected, according to the study published in the journal ” Science Translational Medicine“

A new study limits the cause of blood clots

“Half of the patients who were admitted to the hospital had infection,” said the co-author COVID-19 Were positive for at least one autoantibody, which was very surprising. “

They also found that about half of the patients who were very ill with the virus COVID-19 , They showed a combination of high levels of both dangerous antibodies and a type of destructive and explosive white blood cells.

And in April, the team was the first to report that patients being hospitalized were due to COVID-19 They have higher levels of extracellular white blood cells in their blood.

To find out more, they studied the type of destroyed white blood cells and the antibodies to COVID-19 Together in rat models to see if this could be a dangerous combination behind the thrombosis.

According to the study, I created antibodies taken from infected patients COVID-19 Active ingredients have an amazing amount of clotting in animals – some of the worst COVID-19 To be injured With blood clots.”

COVID-19 blood clots attack from all angles

Researchers say these results are not yet ready for clinical practice, but they are adding a new perspective to robust anticoagulant and inflammatory research in patients with COVID-19.

The team wants to know if severely ill patients who have high levels of these antibodies will have better results if the antibodies are blocked or removed, and if so, this may warrant a more aggressive treatment such as plasma, which is commonly used in diseases. Severe autoimmunity.

“We know that people with the highest levels of autoantibodies performed worse in terms of respiratory function, and the antibodies caused inflammation even in healthy cells,” the researchers say.

They added, “We do not yet know what stimulates the body to produce these antibodies, so the next step will be additional research to determine the triggers and targets of the antibodies.” In addition, these results raise new questions regarding the use of convalescent plasma as a potential treatment for COVID-19 But the team says more research is needed to examine this concern.

Researchers are currently running a randomized clinical trial called DICER , Which is testing a known anticoagulant agent, dipyridamole, in Patients with COVID-19 To determine if it is more effective than placebo in reducing excessive blood clots.

According to them: “Dipyridamole is an old, safe, inexpensive and scalable drug.” The US Food and Drug Administration approved it 20 years ago to prevent thrombosis, but we only recently discovered its ability to prevent this specific type of inflammation that occurs in COVID.”